GC Aesthetics reels in $20M Series D

Dublin
Courtesy of Donaldytong CC BY-SA 3.0

Irish breast implant maker GC Aesthetics completed a $20 million Series D round. The financing will help the company ramp up its commercial operations.

Existing investors Barry’s Tea Holdings, Montreux Equity Partners and Oyster Capital participated, according to a statement. GC Aesthetics previously raised $60 million in 2014, $40 million of which came from new investor Orbimed, with the remaining $20 million from investors including Montreux and Oyster Capital.

The company will use the funds to continue its expansion outside the U.S. These efforts include investing in innovation, improving customer service and launching its leading Impleo product globally, according to the statement.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

GC Aesthetics markets breast implants in more than 75 countries and has about 400 employees. It manufactures more than 325,000 implants each year and last year expanded its customer base by more than 60%, the company said in the statement.

It is the parent company of U.K.-based Nagor and France-based Eurosilicone, both makers of breast implants. It also makes Silgel, which can reduce the appearance of postsurgery scars.

- here's the statement

Related Articles:
Sientra resumes U.S. sales of breast implants after Brazil manufacturing fallout
Sientra slides amid implant manufacturing fallout in Brazil
Upstart Establishment gets $20M+ to bring safer breast implants with nanotech, RFID tracking to U.S.
PIP breast implant scandal a boon to U.K. company

Read more on

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.